Pharming vs Travere Therapeutics
PHAR and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PHAR and TVTX compare
Travere Therapeutics grew revenue faster over the last twelve months (49.4% versus 26.6% for Pharming).
Pharming keeps more of each dollar of sales as profit, with a net margin of 0.76% compared with −18.7% at Travere Therapeutics.
Pharming scores higher on the StockData Score (8 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PHAR | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | – | $4.9B |
| Share price | $13.40 | $52.04 |
| Change, 1 year | −23.6% | 51.4% |
| Change, 5 years | 55.5% | 77.8% |
| Beta (5Y) | 0.56 | 1.14 |
| Employees | 50K | 497 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 7.5× |
| P/B | – | 217× |
| Growth | ||
| Revenue growth (TTM) | 26.6% | 49.4% (better) |
| Revenue growth, 5Y average | 12.1% | 19.9% (better) |
| EPS growth, 5Y average | −40.8% | – |
| Profitability | ||
| Gross margin | 87.9% | 98.5% (better) |
| Operating margin | 6.9% (better) | −20.5% |
| Net margin | 0.76% (better) | −18.7% |
| FCF margin | 14.3% | – |
| Return on equity | – | −253% |
| Financial health | ||
| Interest coverage | 132× (better) | −15.1× |
| Current ratio | 2.59 | 3.00 (better) |
| Altman Z-score | – | 1.77 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.32% | 112% |
| Held by insiders | 0.00% | 1.6% |
| Insider net buying, 12 months | – | −$110M |
| Short interest, % of float | – | 10.3% |
Go deeper
- PHAR stock overview
- PHAR income statement
- PHAR valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.